Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function

NCT00997399 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: panobinostat (LBH589)

Sponsor

Novartis Pharmaceuticals